Showing results (121-130 of 134) with videos related to
Sort By:
Pageof 14
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 20, 2012
A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifenStephen K Chia, Vivien H Bramwell, Dongsheng Tu, et al.European Journal of Cancer (Oxford, England : 1990)|April 25, 2013
A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene Recurrence Score® assay in oestrogen receptor positive node negative breast cancerJ A Davidson, I Cromwell, S L Ellard, et al.Plos One|November 16, 2016
Systematic Review and Meta-Analysis of Randomised Trials to Ascertain Fatal Gastrointestinal Bleeding Events Attributable to Preventive Low-Dose Aspirin: No Evidence of Increased RiskPeter C Elwood, Gareth Morgan, Julieta Galante, et al.British Journal of Cancer|January 11, 2017
Effect of low-dose aspirin use on survival of patients with gastrointestinal malignancies; an observational studyM A Frouws, E Bastiaannet, R E Langley, et al.Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Inhaled LTI-03 for Idiopathic Pulmonary Fibrosis: A Randomized Dose Escalation StudyPhilip L Molyneaux, Nikhil A Hirani, Collin C K Chia, et al.Journal of the National Cancer Institute|May 15, 2023
Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancerEleftherios P Mamounas, Hanna Bandos, Priya Rastogi, et al.Cancer Research Communications|December 5, 2024
Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid TumorsTharani Krishnan, Joao Paulo Solar Vasconcelos, Emma Titmuss, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2024
Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 TrialEleftherios P Mamounas, Hanna Bandos, Priya Rastogi, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2012
Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trialMaggie C U Cheang, K David Voduc, Dongsheng Tu, et al.The Lancet. Oncology|December 5, 2018
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trialEleftherios P Mamounas, Hanna Bandos, Barry C Lembersky, et al.Pageof 14